Summit Therapeutics PLC (LSE:SUMM) - Share price - Overview

Stock Report

Summit Therapeutics PLC SUMM

Last Price
GBX23.50

Day Change
0.00|0.00%

As of 15/02/2019
14:57:36 GMT | GBX
Minimum 15 Minutes Delay.

Last Close23.50p
Day Range22.06 - 23.50
Mkt Cap37.69Mil
52-Wk Range16.30 - 209.00
Yield %-
ISINGB00BN40HZ01
Volume12,629
P/E-2.14
P/S0.01
P/CF-0.01

Share Price

Total Returns 15/02/2019

 Chg (%)  
More ...
Summit Therapeutics PLC-2.08 
FTSE 100 TR GBP5.30
 
Financials
201620172018
More ...
Income Statement
Turnover0.002.3025.42
Operating Profit-20.35-24.32-10.80
Net Profit-20.14-21.37-7.13
Reported EPS-34.00-35.00-11.00
Balance Sheet
Current Assets20.8433.3435.89
Non Current Assets4.224.2518.07
Total Assets25.0637.5953.96
Current Liabilities3.2110.9018.94
Total Liabilities8.9841.0844.09
Total Equity16.08-3.499.88
Cash Flow
Operating Cash Flow-18.589.14-18.06
Net Change in Cash4.9212.47-6.03
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
24/07/2018Exercise of OptionMr. David M. Wurzer1.0019,179192.00
24/07/2018Exercise of OptionMs. Valerie L. Andrews1.0019,179192.00
24/07/2018Exercise of OptionDr. Barry John Price1.0019,179192.00
24/07/2018Sale of OptionDr. Barry John Price36.509,8513,596.00

Company Profile

Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

Sector

Drug Manufacturers - Specialty & Generic

Index

FTSE AIM All-Share

Next Event 11/04/2019

Final Results
Ratios
Comp
More ...
PER (E)1.13
Div Yld (E)0.00
PEG (E)0.00
ROCE-30.83
Op Mrgn-0.43
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive DirectorMr. David M. Wurzer
Non-Executive DirectorMs. Valerie L. Andrews
Non-Executive DirectorDr. Barry John Price
Executive Director, Chief Executive OfficerMr. Glyn Owain Edwards MBE
Non-Executive DirectorProf Stephen Graham Davies
Non-Executive Director, ChairmanDr. Frank Murdoch Armstrong
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.